Moreover, clinical studies carried out to assess the effectiveness of isoflavones in patients with prostate cancer found that isoflavone supplementation significantly reduced the expression of the poor prognostic tumoral marker, prostate specific antigen (PSA), and the expression of androgen receptor (AR), but without effecting the expression of ERβ or circulating hormones. The gene discussed is AR; the disease is prostate carcinoma.